ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
71.855
1.28%
US Dollar vs AUD
1.44716
-0.26%
Bitcoin
66,144.91
1.48%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ZyVersa Therapeutics Inc (ZVSA)

  7. ZyVersa Therapeutics Inc (ZVSA) News

ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ZVSA
DateTimeSourceHeadlineSymbolCompany
17/09/202407:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVSAZyVersa Therapeutics Inc
17/09/202407:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202421:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202421:22Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202406:35Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202406:32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ZVSAZyVersa Therapeutics Inc
10/09/202406:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
04/09/202407:29Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
04/09/202407:28Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVSAZyVersa Therapeutics Inc
31/08/202407:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ZVSAZyVersa Therapeutics Inc
10/08/202406:40GlobeNewswire Inc.ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
10/08/202406:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVSAZyVersa Therapeutics Inc
07/08/202421:50GlobeNewswire Inc.ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic InflammationNASDAQ:ZVSAZyVersa Therapeutics Inc
01/08/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVSAZyVersa Therapeutics Inc
29/07/202421:45GlobeNewswire Inc.ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older AdultsNASDAQ:ZVSAZyVersa Therapeutics Inc
25/07/202421:57GlobeNewswire Inc.ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100NASDAQ:ZVSAZyVersa Therapeutics Inc
19/07/202411:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVSAZyVersa Therapeutics Inc
19/07/202411:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVSAZyVersa Therapeutics Inc
19/07/202411:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVSAZyVersa Therapeutics Inc
19/07/202401:18GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal ModelNASDAQ:ZVSAZyVersa Therapeutics Inc
17/07/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ZVSAZyVersa Therapeutics Inc
09/07/202421:57GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024NASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202422:35GlobeNewswire Inc.ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateNASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVSAZyVersa Therapeutics Inc
15/05/202422:25Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ZVSAZyVersa Therapeutics Inc
14/05/202421:57GlobeNewswire Inc.ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionNASDAQ:ZVSAZyVersa Therapeutics Inc
29/04/202421:57GlobeNewswire Inc.ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseNASDAQ:ZVSAZyVersa Therapeutics Inc
04/04/202422:57GlobeNewswire Inc.ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesNASDAQ:ZVSAZyVersa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVSA

Your Recent History

TSXV
SJR.A
Shaw Communications
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved